see u there
Bloomberg reported after last Phase III Data- SGYP Discussing Buyout w/ Avisors LINK
The Fly On The Wall or Google It
August 1, 2015
Synergy Pharmaceuticals (SGYP) Stock Is Headed For Massive Gains
I’ve got overwhelmingly bullish expectations for Synergy Pharmaceuticals stock. The reality is that the plecanatide study went incredibly well; and following the strong phase 3b results, the company is planning on an NDA submission in the near future. In the world of biotech, these types of things tend to be catalysts that lead to strong growth in the stock the events are represented by. It would also make sense for an acquisition to take place. So, we’ll want to keep an eye out for any developments there as a buyout offer would likely send Synergy Pharmaceuticals soaring in the market. Nonetheless, whether or not a buyout happens, I’m expecting to see strong growth in the long run. Synergy is likely to represent incredibly profitable buying opportunities
Boom.. this is the news longs are waiting for..drones drones drones $$
Sentiment: Strong Buy
What to Expect from Exelixis (EXEL) This Earnings Season?
Yahoo Finance - 1 day ago
The company has an impressive track record, having beat estimates comfortably in the last four quarters
great buy opportunity
A Double-Dose of Bad News Rocks Vertex Pharmaceuticals in September
The big catalyst that weighed on Vertex's stock was the announcement by presidential hopeful Hillary Clinton that she would propose (and impose) a prescription drug reform plan if elected to the oval office. Vertex finds itself directly in the sights of Clinton's proposal, which would cap monthly out-of-pocket costs for consumers at $250 for eligible drugs and focus the governments' efforts on negotiating lower prices with drugmakers. Vertex's two key cystic fibrosis drugs, Kalydeco and Orkambi, come with wholesale costs of just below $300,000 and $259,000, respectively, and they've regularly drawn the ire of consumers who simply can't afford these prices.
The other issue last month was the release of positive phase 1 data from Concert Pharmaceuticals (NASDAQ:CNCE) and its cystic fibrosis drug hopeful CTP-656. In a nine-patient head-to-head with Kalydeco, CTP-656 "achieved a superior pharmacokinetic profile to Kalydeco," according to Concert's press release. Additionally, Concert noted that the increase in plasma levels at the 24-hour mark was due to its parent drug, whereas this wasn't the case with Kalydeco. The vast majority of Vertex's revenue stream is based on its CFdrugs. Thus, if another therapy comes along that is more efficient and/or markedly cheaper, it could spell doom for Vertex.
Booming growth plus new international growth- monster money maker here.
good link from Barron's-Trek Trader Daily By: Tiernan Ray
Sentiment: Strong Buy
See it Market
This Week In IPOs: “Risk-Off”, Boutique Investment Banking And Sickle Cell Disease
August 10, 2015 Investing Research
( GBT )
GBT is developing the initial product candidate, GBT440, as a once-daily, oral prophylactic therapy for sickle cell disease.GBT plans to explore the treatment of more indications, notably hypoxemic pulmonary disorders and hereditary angioedema.
Highlights. Sickle Cell Disease ,Severe disease with major unmet medical need, large market opportunity. Highly experience team with successful track record in developing and commercializing drugs. Co. has contributed to 18 drug approvals
maybe why its going down.